The U.S. Food and Drug Administration (FDA) approved a supplemental application for Keytruda (pembrolizumab) on 2018-12-19. This efficacy-based approval was granted to sponsor Merck Sharp Dohme, indicating an expansion of the drug's approved uses.
Background
Pembrolizumab, marketed as Keytruda, is an established therapeutic agent. Supplemental applications for existing drugs like pembrolizumab are submitted to the FDA to request approval for new indications, patient populations, or changes to dosing or administration that expand the drug's therapeutic utility. This specific approval was classified under 'Efficacy,' indicating a new or expanded use based on demonstrated clinical benefit. Such approvals are a standard part of the drug development lifecycle, allowing medications to serve a wider patient base as new clinical evidence emerges.
What this means
The FDA's approval of this efficacy-based supplemental application for Keytruda (pembrolizumab) signifies an expansion of the drug's approved therapeutic scope. While the specific details of the new indication or patient population are not provided in this data, such approvals are granted when clinical data demonstrates that the drug is safe and effective for an additional use. This allows clinicians to prescribe pembrolizumab to a broader range of patients who may benefit from its therapeutic effects, potentially addressing unmet medical needs in new disease areas or patient subgroups. For patients, this could mean access to Keytruda for conditions or circumstances where it was not previously approved.
Source
The information regarding this approval was sourced from the U.S. Food and Drug Administration (FDA). The supplemental application for Keytruda (pembrolizumab), identified as BLA 125514 S-45, was approved on 2018-12-19 and is detailed on the accessdata.fda.gov website.